Pertussis Clinical Trial
Official title:
The Feasibility of Pertussis Immunization in a Canadian Emergency Department
Verified date | January 2018 |
Source | University of Prince Edward Island |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine to patients presenting to the emergency department. Rates of vaccination as well as effects on department efficiency will be measured.
Status | Completed |
Enrollment | 644 |
Est. completion date | December 20, 2017 |
Est. primary completion date | December 20, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Adults age 18 and above - Have not received Tdap vaccine as an adult (age 18 and above) or have not received Tdap vaccine within 10 years, or unsure of vaccination status Exclusion Criteria: - Acute significant illness (Canadian Triage and Acuity Scale = 1) - Deemed "in too much distress" by triage nurse - Acute Febrile illness - Allergy to vaccine or vaccine components - Pts presenting for wound care (are normally given the vaccine as part of wound care) - Pregnancy < 26 weeks |
Country | Name | City | State |
---|---|---|---|
Canada | Queen Elizabeth Hospital | Charlottetown | Prince Edward Island |
Lead Sponsor | Collaborator |
---|---|
University of Prince Edward Island | The Queen Elizabeth Hospital |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of immunization | Rate of patients receiving Tdap vaccine | One day | |
Secondary | Length of Stay | Length of Stay (mins, secs) for all patients presenting to the emergency. department on study days. | One day | |
Secondary | Left with out being seen rate | Rate of patients leaving without being seen by a physician on study days. | One day | |
Secondary | Time to physician | Time to be seen by emergency physician after triage (mins, secs) on study days. | One day | |
Secondary | Patient refusals | Reasons for patient vaccination refusal | One day | |
Secondary | Nursing satisfaction | Five statements rated on 5 point likert scale (strongly disagree (1) to strongly agree (5)). The immunization strategy significantly increased my workload; patient care was negatively affected by the immunization strategy; I was unable to provide the standard of care because of the immunization strategy; patient flow within the department was negatively affected by the immunization strategy; the ED should implement the immunization strategy | One day | |
Secondary | Additional vaccine received | Additional vaccines administered in the Public Health referral arm | One day | |
Secondary | Triage time | Time (in seconds) required to triage eligible patients in the emergency department | One day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Completed |
NCT02453048 -
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
|
Phase 1 | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT02526394 -
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
|
Phase 4 | |
Completed |
NCT01689324 -
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00804284 -
Database Surveillance Safety Study of PENTACEL® Vaccine
|
N/A | |
Completed |
NCT00514709 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
|
Phase 3 | |
Completed |
NCT00534833 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
|
Phase 3 | |
Completed |
NCT00524732 -
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age
|
N/A | |
Completed |
NCT00772369 -
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
|
Phase 4 | |
Completed |
NCT01457495 -
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
|
Phase 2 | |
Completed |
NCT01267058 -
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00004800 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
|
Phase 3 | |
Completed |
NCT02858440 -
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
|
Phase 3 | |
Recruiting |
NCT04023929 -
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
|
||
Completed |
NCT02946190 -
The PertADO Geneva Trial
|
Phase 2 | |
Completed |
NCT03541499 -
Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults
|
Phase 2 | |
Completed |
NCT02587520 -
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT04589312 -
Maternal Pertussis Wholecell Responses
|
Phase 2 |